Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue
+58.1%
EPS
+142.2%
Free cash flow
+43.5%

Quarter to September 2026, against a year earlier

94.14 5.80 +6.57%
Market cap
$6.9B
P/E
62.1×
Fwd P/E
67.8×
Dividend yield
—
F-score
8/9
Altman Z
10.35
Beneish M
−3.16
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — — — — 3 4 8
P/E ratio
— — — — — 0.00 5.47 97.53 0.00 51.56
P/S ratio
— — — — — 0.00 4.55 4.80 3.34 4.52
Altman Z-Score
— — — — — 4.80 9.38 8.00 5.66 10.35
Altman Z″-Score (non-manufacturers)
— — — — — (5.64) 6.00 4.64 2.40 5.08
P/FCF ratio
— — — — — 0.00 177.86 97.89 55.34 22.42
Beneish M-Score
— — — — — — 4.22 (2.01) (2.43) (3.16)
P/Operating CF
— — — — — (42.74) (86.55) 300.16 75.27 56.79
P/B ratio
— — — — — 4.36 2.53 2.96 3.22 5.39
EV/Sales
— — — — — 0.00 3.68 4.04 2.76 3.91
EV/EBITDA
— — — — — 0.00 66.63 0.00 0.00 33.60
EV/FCF
— — — — — (4.26) 144.02 82.33 45.80 19.39
Current Ratio
24.47 2.70 7.37 8.68 10.46 4.38 5.16 4.34 3.30 3.79
Net Debt/EBITDA
2.34 0.70 2.85 1.39 2.09 1.18 (15.66) 9.03 5.55 (5.26)
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
41.53% 112.39% (108.91%) (64.15%) (60.06%) (63.55%) 63.10% 3.37% (9.85%) 11.73%
ROA
(46.12%) (124.80%) (55.88%) (56.16%) (53.44%) (54.24%) 52.96% 2.86% (7.80%) 8.78%
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% (3,451.96%) 2.97% (6.77%) (14.63%) 31.44%
Return on Tangible Assets
(44.30%) (217.70%) (37.19%) (73.51%) (52.83%) (102.25%) 92.77% 6.60% (18.63%) 15.13%
Average Days of Receivables
— — — — — 37.74 20.99 28.72 35.98 8.40
Earnings Yield
— — — — — (19.54%) 18.28% 1.03% (3.08%) 1.94%
Free Cash Flow Yield
— — — — — (18.18%) 0.56% 1.02% 1.81% 4.46%
Free Cash Flow per Share
(83.57) (27.78) (2.92) (2.99) (2.21) (2.14) 0.08 0.19 0.36 1.84
Book value per Share
206.97 16.61 9.45 4.17 5.04 2.70 5.71 6.26 6.14 7.65
Free Cash Flow
(21.87) (50.29) (86.30) (161.57) (136.81) (146.71) 5.79 13.17 25.44 136.42
EV/EBIT
— — — — — 0.00 83.01 0.00 0.00 34.27
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026